Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC28A1 | O00337 | 1/20 | 0.68 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.68 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.68 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.68 |
| ▸ | P2RY2 | P41231 | 9/20 | 0.49 |
| ▸ | P2RY6 | Q15077 | 8/20 | 0.49 |
| ▸ | P2RY14 | Q15391 | 6/20 | 0.49 |
| ▸ | P2RY4 | P51582 | 5/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14402924 | 0.91 | SLC28A1 (0.63) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| SCHEMBL5221715 | 0.91 | SLC28A1 (0.63) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| SCHEMBL10081934 | 0.91 | SLC28A1 (0.63) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| SCHEMBL28804995 | 0.90 | SLC28A1 (0.73) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| SCHEMBL23928762 | 0.89 | SLC28A1 (0.68) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| SCHEMBL18720102 | 0.89 | SLC28A1 (0.68) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| SCHEMBL19726985 | 0.89 | SLC28A1 (0.68) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| SCHEMBL4453556 | 0.89 | SLC28A1 (0.68) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| SCHEMBL4453558 | 0.89 | SLC28A1 (0.68) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| SCHEMBL20815980 | 0.88 | SLC28A1 (0.71) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12472267-B2 | Compositions containing nucleic acid nanoparticles with modular functionality | Sixfold Bioscience Ltd. (GB) | 2025-11-18 | — | — | US | disclosed |
| US-20250188478-A1 | siRNA SUPPRESSING EXPRESSION OF TRANSFERRIN RECEPTOR 2 | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2025-06-12 | — | — | US | disclosed |
| US-20250188477-A1 | CHEMICALLY MODIFIED OLIGONUCLEOTIDE HAVING RNAi ACTIVITY | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2025-06-12 | — | — | US | disclosed |
| WO-2025110249-A1 | COMPOSITION FOR NUCLEOTIDE SEQUENCE EDITING, AND NUCLEOTIDE SEQUENCE EDITING METHOD USING SAME | 国立大学法人 広島大学 | 2025-05-30 | — | — | WO | disclosed |
| WO-2025063238-A1 | SIRNA FOR SUPPRESSING EXPRESSION OF PHOSPHOLAMBAN | 第一三共株式会社 | 2025-03-27 | — | — | WO | disclosed |
| WO-2025063239-A1 | SIRNA CAPABLE OF SUPPRESSING EXPRESSION OF α-SYNUCLEIN | 第一三共株式会社 | 2025-03-27 | — | — | WO | disclosed |
| EP-4495241-A1 | CHEMICALLY-MODIFIED OLIGONUCLEOTIDE HAVING RNAI ACTIVITY | Daiichi Sankyo Company, Limited (JP) | 2025-01-22 | — | — | EP | disclosed |
| EP-4495240-A1 | SIRNA FOR SUPPRESSING EXPRESSION OF TRANSFERRIN RECEPTOR-2 | Daiichi Sankyo Company, Limited (JP) | 2025-01-22 | — | — | EP | disclosed |
| CN-119326905-A | GalNAc-oligonucleotide conjugate for delivery to liver and preparation method thereof | 第一三共株式会社 | 2025-01-21 | — | — | CN | disclosed |
| CN-114616332-B | GalNAc-oligonucleotide conjugate for delivery to liver and preparation method thereof | 第一三共株式会社 | 2024-09-20 | — | — | CN | disclosed |
| US-20220370635-A1 | COMPOSITIONS CONTAINING NUCLEIC ACID NANOPARTICLES WITH MODULAR FUNCTIONALITY | SIXFOLD BIOSCIENCE LTD (GB) | 2022-11-24 | — | — | US | disclosed |
| US-20220364086-A1 | ANTISENSE OLIGONUCLEOTIDE CAPABLE OF ALTERING SPLICING OF DUX4 pre-mRNA | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2022-11-17 | — | — | US | disclosed |
| EP-4029520-A1 | GALNAC-OLIGONUCLEOTIDE CONJUGATE FOR LIVER-TARGETED DELIVERY USE, AND METHOD FOR PRODUCING SAME | Daiichi Sankyo Company, Limited (JP) | 2022-07-20 | — | — | EP | disclosed |
| US-11357865-B2 | Compositions containing nucleic acid nanoparticles with modular functionality | Sixfold Bioscience Ltd. (GB) | 2022-06-14 | — | — | US | disclosed |
| CN-114616332-A | GalNAc-oligonucleotide conjugates for delivery to liver and methods of making the same | 第一三共株式会社 | 2022-06-10 | — | — | CN | disclosed |
| EP-3998108-A1 | ANTISENSE OLIGONUCLEOTIDE CAPABLE OF ALTERING SPLICING OF DUX4 PRE-MRNA | Daiichi Sankyo Company, Limited (JP) | 2022-05-18 | — | — | EP | disclosed |
| WO-2021220053-A2 | COMPOSITIONS CONTAINING NUCLEIC ACID NANOPARTICLES WITH MODULAR FUNCTIONALITY | Sixfold Bioscience Ltd. (GB) | 2021-11-04 | — | — | WO | disclosed |
| US-20210330810-A1 | COMPOSITIONS CONTAINING NUCLEIC ACID NANOPARTICLES WITH MODULAR FUNCTIONALITY | Sixfold Bioscience Ltd. (GB) | 2021-10-28 | — | — | US | disclosed |
| WO-2021112106-A1 | XERODERMA PIGMENTOSUM GROUP F THERAPEUTIC AGENT | 第一三共株式会社 | 2021-06-10 | — | — | WO | disclosed |
| US-20140350080-A1 | INHIBITION OF VIRAL GENE EXPRESSION | UNIVERSITY OF THE WITWATERSRAND, JOHANNESBURG (ZA) | 2014-11-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11357865-B2 | Compositions containing nucleic acid nanoparticles with modular functionality | NCL, NSUN3, POLN | SLC28A1 3646/4885SLC28A2 3993/4885SLC29A1 840/4885 |
| US-20220370635-A1 | COMPOSITIONS CONTAINING NUCLEIC ACID NANOPARTICLES WITH MODULAR FUNCTIONALITY | NCL, NSUN3, POLN | SLC28A1 3646/4885SLC28A2 3993/4885SLC29A1 840/4885 |
| US-20250188478-A1 | siRNA SUPPRESSING EXPRESSION OF TRANSFERRIN RECEPTOR 2 | TFRC, FOLR2, FTH1 | SLC28A1 168/4885SLC28A2 42/4885SLC29A1 390/4885 |
| US-20210330810-A1 | COMPOSITIONS CONTAINING NUCLEIC ACID NANOPARTICLES WITH MODULAR FUNCTIONALITY | NCL, NSUN3, POLN | SLC28A1 3646/4885SLC28A2 3993/4885SLC29A1 840/4885 |
| US-12472267-B2 | Compositions containing nucleic acid nanoparticles with modular functionality | NCL, NSUN3, POLN | SLC28A1 3646/4885SLC28A2 3993/4885SLC29A1 840/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.